Arcus Biosciences, Inc. (RCUS) News
Filter RCUS News Items
RCUS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RCUS News Highlights
- RCUS's 30 day story count now stands at 2.
- Over the past 6 days, the trend for RCUS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest RCUS News From Around the Web
Below are the latest news stories about ARCUS BIOSCIENCES INC that investors may wish to consider to help them evaluate RCUS as an investment opportunity.
Arcus Biosciences Announces New Employment Inducement GrantsHAYWARD, Calif., September 11, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 35,400 shares of the Company’s common stock at an exercise price per share of $21.38, which was the closing price on September 8, 2023, |
Arcus Biosciences (RCUS): A Modestly Undervalued Gem?An In-Depth Analysis of Its Market Value |
Biotech Stocks Rally After Roche's (RHHBY) Accidental Data LeakShares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data. |
Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer StudyRoche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for another dive into the biggest pre-market stock movers as we break down all of the biggest news on Wednesday! |
Arcus Biosciences: A Modestly Undervalued Opportunity?An in-depth valuation analysis of Arcus Biosciences Inc (RCUS) |
Arcus Biosciences to Participate in Multiple Upcoming Investor ConferencesHAYWARD, Calif., August 23, 2023--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September: |
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue EstimatesArcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -4% and 19.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline UpdateHAYWARD, Calif., August 07, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple common cancers. |
Prothena (PRTA) Reports Q2 Loss, Lags Revenue EstimatesProthena (PRTA) delivered earnings and revenue surprises of -11.96% and 62%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |